Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2022; 13(10): 835-850
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.835
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.835
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Geza Nagy, Tekla Evelin Szekely, Aniko Somogyi, Magdolna Herold, Department of Internal Medicine and Hematology, Semmelweis University, Budapest H-1088, Hungary
Zoltan Herold, Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest H-1083, Hungary
Author contributions: Nagy G and Szekely TE wrote the manuscript with the support of Somogyi A, Herold M and Herold Z.
Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Geza Nagy, MD, PhD, Assistant Professor, Department of Internal Medicine and Hematology, Semmelweis University, Szentkiralyi u. 46, Budapest H-1088, Hungary. nagy.geza@med.semmelweis-univ.hu
Received: May 28, 2022
Peer-review started: May 28, 2022
First decision: August 1, 2022
Revised: August 8, 2022
Accepted: September 15, 2022
Article in press: September 15, 2022
Published online: October 15, 2022
Processing time: 138 Days and 16.3 Hours
Peer-review started: May 28, 2022
First decision: August 1, 2022
Revised: August 8, 2022
Accepted: September 15, 2022
Article in press: September 15, 2022
Published online: October 15, 2022
Processing time: 138 Days and 16.3 Hours
Core Tip
Core Tip: Our knowledge is rapidly growing about the pathomechanism of type 1 diabetes mellitus, and new and improved therapies have emerged. However, the long-term complications and the required lifestyle changes cannot be eliminated. There is a growing number of research that aims to find specific immunological markers/targets that have a role in disease development. The ultimate goal is finding new therapeutic ways to treat the disease and to delay or even prevent its development. The aim of this review was to provide a brief insight into the current state of disease-modifying therapeutic interventions that may impact future diabetes care.